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Purpose: To report age-specific serum estradiol concentration in nonsmoking, lean US men without
comorbidities. We provide concentrations from 30 and 15 to 20 years ago given previously described
declines in serum estradiol in US men over time.
Methods:We used data from the Third National Health and Nutrition Examination Survey (NHANES
III; 1988 to 1991) and continuous NHANES (1999 to 2004). Serum estradiol and SHBGwere previously
measured by competitive electrochemiluminescence immunoassays. Free estradiol was estimated from
estradiol, SHBG, and albumin. By age, we calculated median concentrations overall and for non-
smoking, lean (body mass index ,25 kg/m2 and waist ,102 cm) men without diabetes, cardiovascular
disease, or cancer.
Results:Overall, respective total estradiol medians for men ages 20 to 39, 40 to 59, and$60 years old
were 37.0, 33.9, and 33.5 pg/mL in NHANES III and 31.3, 30.5, and 27.0 pg/mL in continuous
NHANES. In nonsmoking, lean men without comorbidities, respective total estradiol medians were
32.0, 32.1, and 32.0 pg/mL in NHANES III and 29.1, 22.7, and 26.1 pg/mL in continuous NHANES.
Overall, respective free estradiol medians were 0.82, 0.72, and 0.64 pg/mL in NHANES III and 0.67,
0.61, and 0.47 pg/mL in continuous NHANES. In nonsmoking, lean men without comorbidities,
respective free estradiol medians were 0.64, 0.67, and 0.62 pg/mL in NHANES III and 0.58, 0.42, and
0.40 pg/mL continuous NHANES.
Conclusion: We report US nationally representative serum estradiol concentrations in healthy men,
which could be used for targeting estradiol during testosterone supplementation and for general
good health.
Copyright © 2019 Endocrine Society
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Symptoms accompanying testosterone deficiency are often treated with testosterone sup-
plementation. Such treatment could lead to higher estradiol levels via peripheral aroma-
tization of testosterone to estradiol in adipose tissue [1], especially in men with excess body
fat. Increases in circulating estradiol as a result of testosterone supplementation may be
clinically important for at least two reasons. First, gynecomastia, which has a prevalence of
one- to two-thirds of men overall [2] and #70% in men 50 to 69 years old [3], can be exac-
erbated by replacement testosterone. Indeed, the recent American Urological Association
(AUA) Clinical Practice Guidelines for the Evaluation and Management of Testosterone
Deficiency recommended that estradiol levels be measured in men with breast symptoms or
gynecomastia before supplemental testosterone therapy or during therapy if breast symp-
toms or gynecomastia developed [4]. However, neither the AUA [4] nor the Endocrine Society
[5] recommends measuring estradiol levels before prescribing testosterone for other men
being considered for supplementation. Second, elevated circulating estradiol levels have been
associated with altered inflammatory and immune responses in men [6], including higher
concentrations of circulating proinflammatory markers [7].
The typical laboratory reference range for serum estradiol in men is 10 to 40 pg/mL [8].
However, serum estradiol ranges have not been established for optimal health for older men,
such as those without common chronic diseases, who are not overweight or obese, and who do
not smoke, all factors that can influence these levels. Age-specific estradiol ranges for healthy
men could be useful as clinical targets for men receiving testosterone supplementation. In
addition, age-specific estradiol ranges, both low and high, could be used as targets for overall
well-being among men, given that estradiol has beneficial effects in men as they age, in-
cluding reducing the risk of osteopenia [9].
To support the implementation of clinical guidelines for serum estradiol concentrations for
men with symptomatic testosterone deficiency who are candidates for testosterone sup-
plementation, and for men in general for good health, we report total and estimated free
estradiol concentrations in nationally representative samples of younger, middle-aged, and
older nonsmoking, lean men without common chronic diseases. Given the known racial and
ethnic differences in estradiol concentration in men [10], we also report estradiol concen-
trations by race and ethnicity. We provide information at two time points, about 30 years and
15 to 20 years ago, given the previously reported but unexplained decline in serum estradiol
concentration in men in the United States [11].
1. Methods
A. Study Population
We used data from The Third National Health andNutrition Examination Survey (NHANES
III) and three continuous NHANES surveys. NHANES III, conducted between 1988 and
1994, examined 30,818 participants; NHANES 1999 to 2000 examined 9282 participants;
NHANES 2001 to 2002 examined 10,122 participants; and NHANES 2003 to 2004 examined
9643 participants. Each survey is a cross-sectional study designed to assess the health and
nutritional status of the US population [12, 13]. In each survey, participants were sampled by
multistage probability sampling. Evaluations involved home interviews, standard physical
examinations, and laboratory tests.
We used serum total estradiol data previouslymeasured inmenwho had their blood drawn
in themorning session (NHANES III phase I only, N5 1462 [14]; NHANES, 1999 to 2004N5
978 [11]). We includedmen$20 years old with nomissing data on smoking, weight, height, or
waist circumference (WC). A priori we excluded men taking medications that influence sex
steroid hormone levels, specifically androgens, anabolic steroids, 5-a-reductase inhibitors,
and antigonadotropic agents. After exclusions, we included in the total estradiol analysis 673
non-Hispanic white, 360 non-Hispanic black, and 373Mexican Americanmen fromNHANES
III and 507 non-Hispanic white, 187 non-Hispanic black, and 216 Mexican American men
from NHANES 1999 to 2004.
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B. Serum Estradiol
We used data on serum estradiol and SHBG, which were previously measured [11, 14] at
Boston Children’s Hospital with a competitive electrochemiluminescence immunoassay on
the 2010 Elecsys autoanalyzer (Roche Diagnostics, Indianapolis, IN). Because the NHANES
III and NHANES 1999 to 2004 specimens were assayed at different times, a comparability
study was previously conducted; the coefficient of variation (CV) for estradiol concentrations
for a subset of the NHANES III samples compared the original measurement and the
measurement of the same NHANES III samples assayed at the time as the continuous
NHANES sample were assayed. The CV was 15.3% [11]. Albumin was measured as part of
the NHANES protocol with a Beckman Synchron LX20. Free estradiol was calculated by
mass action with each man’s estradiol, SHBG, and albumin concentrations [15].
C. Covariates
Covariates were obtained from the NHANES examinations and interviews. Age, race, and
cigarette smoking status were self-reported. Wemaintained the same definitions for race as in
the NHANES III and the NHANES 1999 to 2004. We defined nonsmokers as never smokers
(smoked ,100 cigarettes over the lifetime) and former smokers. Body mass index (BMI) was
calculated by dividing weight in kilograms by the square of height (measured to the nearest
0.1 cm) in meters. WC was measured along the iliac crest to the nearest 0.1 cm at minimal
respiration. Common chronic diseases were self-reported in response to questions onwhether a
doctor ever told them they had heart failure or heart attack, diabetes, or cancer. Use of
prescription medications in the last 30 days was determined by interview along with physical
container confirmation, where possible.
D. Statistical Analysis
After sampling weights were applied, separately for NHANES III and NHANES 1999 to 2004
and by younger (20 to 39 years), middle (40 to 59 years), and older ($60 years) adult age, the
mean and SE (calculated via the Taylor series linearization method), 10th percentile, 25th
percentile, median, 75th percentile, and 90th percentile of total and estimated free estradiol
were calculated overall and among men categorized as follows: men with both BMI ,25 kg/m2
and WC ,102 cm [16]; men without a physician diagnosis of congestive heart failure, heart
attack, stroke, diabetes, or cancer; and men with both BMI ,25 kg/m2 and WC ,102 cm and
without congestive heart failure, heart attack, stroke, diabetes, or cancer. Next, we repeated
these analyses excluding current smokers, because in our previous work in NHANES III,
current smokers had higher estradiol concentrations than both never and former smokers, who
had similar mean total and free estradiol [17]. Finally, we repeated all these analyses stratified
by race and ethnicity.
2. Results
In the NHANES III study population, 39.0%were 20 to 39 years, 29.8% were 40 to 59 years, and
31.2% were$60 years old; 46.0% were non-Hispanic white, 24.6% were non-Hispanic black, and
25.5%wereMexicanAmerican; 68.5%werenonsmokers; 41.5%hadaBMI,25kg/m2; and 69.4%
had aWC,102 cm (Table 1). In the NHANES 1999 to 2004 study population, 36.2% were 20 to
39 years, 31.6% were 40 to 59 years, and 32.2% were $60 years old; 51.8% were non-Hispanic
white, 19.1% were non-Hispanic black, and 22.1% were Mexican American; 73.3% were non-
smokers; 30.9% had a BMI ,25 kg/m2; and 58.2% had a WC ,102 cm (Table 1).
A. Total Estradiol
Median total estradiol concentrations in both NHANES III and NHANES 1999 to 2004 are
listed in Table 2, including median concentrations for nonsmokers alone. All results stated
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below refer to Table 2, and unstated full distributions are listed in the supplemental tables
[18]. For all men, the respectivemedian total estradiol concentrations amongmen 20 to 39, 40
to 59, and $60 years old were 37.0, 33.9, and 33.5 pg/mL in NHANES III and 31.3, 30.5, and
27.0 pg/mL inNHANES 1999 to 2004 [18]. For leanmenwithout comorbidities, medianswere
similar to those for all men in both NHANES III and NHANES 1999 to 2004: respective
median total estradiol concentrations were 37.5, 33.2, and 34.5 pg/mL in NHANES III and
32.4, 29.6, and 29.8 pg/mL in NHANES 1999 to 2004. For nonsmoking men, total estradiol
concentrations were generally slightly lower than for all men: the respective median total
Table 1. Characteristics ofMenWhoParticipated in NHANES III (1988–1994) and Continuous NHANES
(1999– 2004)
NHANES III NHANES 1999–2004
N 1462 978
Age group, N (%)
20–39 y 570 (39.0%) 354 (36.2%)
40–59 y 436 (29.8%) 309 (31.6%)
$60 y 456 (31.2%) 315 (32.2%)
Race and ethnicity, N (%)
Non-Hispanic white 673 (46.0%) 507 (51.8%)
Non-Hispanic black 360 (24.6%) 187 (19.1%)
Mexican American 373 (25.5%) 216 (22.1%)
Other 56 (3.8%) 68 (7.0%)
BMI ,25 kg/m2, N (%) 607 (41.5%) 302 (30.9%)
WC ,102 cm, N(%) 1014 (69.4%) 569 (58.2%)
Nonsmokers,a N (%) 1001 (68.5%) 717 (73.3%)
No comorbidities,b N (%) 1200 (82.1%) 743 (76.0%)
aNonsmokers are never and former smokers.
bNo congestive heart failure, heart attack, stroke, diabetes, or cancer.
Table 2. Median Total Estradiol by Age Among All Men and Among Men Without Health States That
Influence Estradiol, NHANES III (1988–1994) and NHANES 1999–2004
Median Total Estradiol (pg/mL)
20–39 y 40–59 y 601 y
NHANES III (1988–1994)
All men 37.0 33.9 33.5
Lean mena 37.5 33.2 32.6
Men without comorbiditiesb 37.0 33.8 32.7
Lean men without comorbidities 37.5 33.2 34.5
Nonsmoking menc 33.8 32.2 32.6
Nonsmoking lean men 32.1 32.1 31.9
Nonsmoking men without comorbidities 33.7 32.2 31.9
Nonsmoking lean men without comorbidities 32.0 32.1 32.0
NHANES 1999–2004
All men 31.3 30.5 27.0
Lean men 32.4 29.5 27.2
Men without comorbidities 31.4 30.1 26.8
Lean men without comorbidities 32.4 29.6 29.8
Nonsmoking men 29.7 26.5 26.6
Nonsmoking lean men 29.0 24.1 23.4
Nonsmoking men without comorbidities 29.7 26.4 25.7
Nonsmoking lean men without comorbidities 29.1 22.7 26.1
aBMI ,25 kg/m2 and WC ,102 cm.
bWithout congestive heart failure, heart attack, stroke, diabetes, or cancer.
cNever or former smokers.
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estradiol concentrations were 33.8, 32.2, and 32.6 pg/mL in NHANES III and 29.7, 26.5, and
26.6 pg/mL in NHANES 1999 to 2004 [18]. For nonsmoking, lean men without comorbidities
in NHANES III, median total estradiol concentrations were similar to those for all men
except 20- to 39-year-old men, whereas in NHANES 1999 to 2004, medians were lower for
middle-aged and older men, although themedian appeared similar formen 20 to 29 years old:
the respective median total estradiol concentrations were 32.0, 32.1, and 32.0 pg/mL in
NHANES III and 29.1, 22.7, and 26.1 pg/mL in NHANES 1999 to 2004.
B. Estimated Free Estradiol
Median free estradiol concentrations in both NHANES III and NHANES 1999 to 2004 are
listed in Table 3, including median concentrations in nonsmokers alone. All results stated
below refer to Table 3, and unstated full distributions are listed in the supplemental tables
[18]. The analysis for estimated free estradiol was based on the 1445 men (98.8%) in
NHANES III and 973 men (99.8%) in NHANES 1999 to 2004 who additionally had SHBG
concentrations available. For all men, the respective median free estradiol concentrations
amongmen 20 to 39, 40 to 59, and$60 years old were 0.82, 0.72, and 0.64 pg/mL in NHANES
III and 0.67, 0.61, and 0.47 pg/mL in NHANES 1999 to 2004 [18]. For lean men without
comorbidities, free estradiol concentrations were slightly lower than for all men in both
NHANES III and NHANES 1999 to 2004: the respective medians were 0.78, 0.67, and 0.65
pg/mL in NHANES III and 0.64, 0.54, and 0.48 pg/mL in NHANES 1999 to 2004. For
nonsmoking men, free estradiol concentrations were generally lower than concentrations for
all younger and middle-aged men in NHANES III and middle-aged men in NHANES 1999 to
2004, whereas for older men free estradiol concentrations were similar in both NHANES III
and NHANES 1999 to 2004: the respective medians were 0.75, 0.70, and 0.62 pg/mL in
NHANES III and 0.68, 0.57, and 0.46 pg/mL in NHANES 1999 to 2004 [18]. For nonsmoking,
lean men without comorbidities, median free estradiol concentrations were lower than for all
men in both NHANES III and NHANES 1999 to 2004, except for older men in NHANES III,
Table 3. Median Free Estradiol by Age Among All Men and Among Men Without Health States That
Influence Estradiol, NHANES III (1988–1994) and NHANES 1999–2004
Median Free Estradiol (pg/mL)
20–39 y 40–59 y 601 y
NHANES III (1988–1994)
All men 0.82 0.72 0.64
Lean mena 0.78 0.68 0.63
Men without comorbiditiesb 0.82 0.72 0.64
Lean men without comorbidities 0.78 0.67 0.65
Nonsmoking menc 0.75 0.70 0.62
Nonsmoking lean men 0.64 0.67 0.60
Nonsmoking men without comorbidities 0.75 0.69 0.62
Nonsmoking lean men without comorbidities 0.64 0.67 0.62
NHANES 1999–2004
All men 0.67 0.61 0.47
Lean men 0.64 0.54 0.41
Men without comorbidities 0.67 0.61 0.47
Lean men without comorbidities 0.64 0.54 0.48
Nonsmoking men 0.68 0.57 0.46
Nonsmoking lean men 0.58 0.44 0.35
Nonsmoking men without comorbidities 0.67 0.57 0.44
Nonsmoking lean men without comorbidities 0.58 0.42 0.40
aBMI ,25 kg/m2 and WC ,102 cm.
bWithout congestive heart failure, heart attack, stroke, diabetes, or cancer.
cNever or former smokers.
doi: 10.1210/js.2019-00178 | Journal of the Endocrine Society | 1829
whose concentrations were similar: respective medians were 0.64, 0.67, and 0.62 pg/mL in
NHANES III and 0.58, 0.42, and 0.40 pg/mL in NHANES 1999 to 2004. Given that free
estradiol was calculated with SHBG, we also provide distributions for SHBG in an online
repository [18].
C. Race and Ethnicity
C-1. Estimated total estradiol
Median total estradiol concentrations in both NHANES III and NHANES 1999 to 2004 by
race and ethnicity are listed in Table 4, includingmedian concentrations in nonsmokers alone
(unstated full distributions are listed in an online repository [18]). For lean men without
comorbidities, median total estradiol concentrations were not consistently different from
those for all men within their respective race and ethnicity group (Table 4). For nonsmoking,
lean men without comorbidities, median total estradiol concentrations were generally lower
than for all men within their respective race and ethnicity group, except among non-Hispanic
black men in NHANES 1999 to 2004 (Table 4).
Table 4. MedianTotal Estradiol byAge andRace andEthnicity AmongAllMenandAmongMenWithout
Health States That Influence Estradiol, NHANES III (1988–1994) and NHANES 1999–2004
Median Total Estradiol (pg/mL)
20–39 y 40–59 y 601 y
NHANES III (1988–1994)
Non-Hispanic white
All men 36.5 33.6 34.0
Lean mena without comorbiditiesb 36.4 32.7 35.3
Nonsmoking menc 33.2 32.3 33.2
Nonsmoking lean men without comorbidities 31.5 32.1 32.8
Non-Hispanic black
All men 45.5 39.0 38.8
Lean men without comorbidities 44.8 38.2 31.9
Nonsmoking menc 44.8 35.7 36.5
Nonsmoking lean men without comorbidities 44.8 35.3 28.1
Mexican American
All men 33.7 32.4 32.8
Lean men without comorbidities 33.8 35.9 34.5
Nonsmoking menc 32.3 30.8 32.8
Nonsmoking lean men without comorbidities 31.7 31.6 35.0
NHANES 1999–2004
Non-Hispanic white
All men 28.1 30.9 26.7
Lean men without comorbidities 29.7 29.1 26.5
Nonsmoking menc 28.3 25.8 25.6
Nonsmoking lean men without comorbidities 27.9 20.1 21.5
Non-Hispanic black
All men 36.5 36.9 33.3
Lean men without comorbidities 41.3 35.3 30.7
Nonsmoking menc 35.0 35.7 34.0
Nonsmoking lean men without comorbidities 38.6 19.5 38.1
Mexican American
All men 28.1 25.2 22.3
Lean men without comorbidities 28.9 20.5 8.6
Nonsmoking menc 27.2 23.3 22.3
Nonsmoking lean men without comorbidities 27.4 17.3 5.9
aBMI , 25 kg/m2 and WC , 102 cm.
bWithout congestive heart failure, heart attack, stroke, diabetes, or cancer.
cNever or former smokers.
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C-2. Estimated free estradiol
Median free estradiol concentrations in bothNHANES III andNHANES 1999 to 2004 by race
and ethnicity are listed in Table 5, including median concentrations in nonsmokers alone
(unstated full distributions are listed in an online repository [18]). For lean men without
comorbidities, median free estradiol concentrations were lower than for all men within their
respective race and ethnicity group, except inNHANES III amongmen 601 years old who are
non-Hispanic white and Mexican American (Table 5). The same patterns were present for
nonsmoking, lean men without comorbidities (Table 5).
3. Discussion
Using data from two US nationally representative surveys conducted about 30 and 15 to
20 years ago, we reported serum total and estimated free estradiol concentrations in younger,
middle-age, and older healthy men. Because of the recognized differences in estradiol con-
centration between racial and ethnic groups [10], including in NHANES III and continuous
Table 5. Median Free Estradiol by Age andRace andEthnicity AmongAllMen andAmongMenWithout
Health States That Influence Estradiol, NHANES III (1988–1994) and NHANES 1999–2004
Median Free Estradiol (pg/mL)
20–39 y 40–59 y 601 y
NHANES III (1988–1994)
Non-Hispanic white
All men 0.80 0.72 0.64
Lean mena without comorbiditiesb 0.75 0.67 0.65
Nonsmoking menc 0.73 0.70 0.63
Nonsmoking lean men without comorbidities 0.62 0.67 0.63
Non-Hispanic black
All men 0.95 0.78 0.72
Lean men without comorbidities 0.90 0.73 0.54
Nonsmoking menc 0.93 0.75 0.64
Nonsmoking lean men without comorbidities 0.92 0.68 0.49
Mexican American
All men 0.75 0.69 0.63
Lean men without comorbidities 0.69 0.61 0.66
Nonsmoking menc 0.70 0.68 0.63
Nonsmoking lean men without comorbidities 0.66 0.58 0.69
NHANES 1999–2004
Non-Hispanic white
All men 0.66 0.61 0.45
Lean men without comorbidities 0.63 0.50 0.40
Nonsmoking menc 0.68 0.55 0.44
Nonsmoking lean men without comorbidities 0.59 0.38 0.33
Non-Hispanic black
All men 0.82 0.74 0.61
Lean men without comorbidities 0.74 0.66 0.52
Nonsmoking menc 0.79 0.74 0.63
Nonsmoking lean men without comorbidities 0.71 0.36 0.64
Mexican American
All men 0.61 0.51 0.44
Lean men without comorbidities 0.60 0.34 0.16
Nonsmoking menc 0.59 0.51 0.43
Nonsmoking lean men without comorbidities 0.57 0.31 0.11
aBMI , 25 kg/m2 and WC , 102 cm.
bWithout congestive heart failure, heart attack, stroke, diabetes, or cancer.
cNever or former smokers.
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NHANES 1999 to 2004 [11, 14], we also reported age-specific serum total and free estradiol
concentrations among healthy men by racial and ethnic groups (non-Hispanic white, non-
Hispanic black, andMexican American). The context for this work was to provide information
that could be used inmonitoring estradiol levels during testosterone supplementation and for
good health in general.
One purpose of our report is to inform the monitoring of serum estrogen in men receiving
testosterone supplementation. Although the literature on the influence of testosterone
supplementation on estrogen levels is not extensive, the influence of testosterone supple-
mentation on estradiol levels is supported by the fact that somemen who receive testosterone
therapy develop estrogen-related symptoms such as gynecomastia and by direct measure-
ments of their serum estradiol concentrations. For example, in a 2015 study by Tan et al. [19],
of 34,016 men treated for low testosterone across 35 US sites, 20.2% had high estradiol levels,
defined as .42.6 pg/mL as measured by electrochemiluminescence immunoassay.
Risks of supplemental testosterone, including estrogen-associated symptoms, have been
discussed extensively in the literature and summarized in consensus practice guidelines [5].
However, other possible consequences of increased estrogen levels, whether caused by
testosterone supplementation or other factors, have been not been discussed in the same
depth. Some studies have reported that estrogen influences carcinogenesis via genomic and
nongenomic processes. For example, estrogens can produce DNA damage after being me-
tabolized to catechols [20, 21]. Of particular interest for older men, evidence from animal
studies suggests a synergistic role for estrogens in prostate carcinogenesis [6, 22]. In rats,
although prostate cancer can be induced by androgens alone, a higher chance of inducing
prostate cancer occurs when the combination of androgens and estrogen is administered [6,
22]. However, a large, pooled analysis of epidemiologic studies on circulating estrogens
measured once in middle or older age and prostate cancer risk does not support a link [23].
Nevertheless, elevated estrogens, irrespective of the cause, could generate chronic, systemic
inflammation; men with higher estrogens have higher white blood cell counts and C-reactive
protein concentrations and consequent adverse effects on health in general [7]. Although it
remains unknown whether circulating estradiol levels influence intraprostatic inflammation
in men, as has been observed in rodents [24], such a possibility is concerning given that
intraprostatic inflammation has been associated with an elevated risk of prostate cancer
[25, 26].
We reported medians and distributions of estradiol concentrations in healthy men who
participated in the morning sessions of phase I of NHANES in 1988 to 1991 or in continuous
NHANES in 1999 to 2004. Although the medians were different, patterns of total and free
estradiol concentrations were similar at these two time points. We reported data separately
by time point because members of our team previously published that estradiol concen-
trations, adjusted for BMI, WC, and smoking, decreased between the years of these two
surveys among non-Hispanic white and Mexican American men [11]. These declines could be
the result of secular changes in the prevalences of factors that directly or indirectly influence
serum estradiol, although we could not rule out time differences. However, the samples were
assayed in the same laboratory by the same method. As noted above, a small number of the
NHANES III samples were reanalyzed when the NHANES 1999 to 2004 samples were
assayed, and there was a CV of 15.3%, which was not unexpected for this analyte, which has a
low concentration in men [11].
To capture estradiol levels in healthy men, we made several restrictions. First, we re-
stricted the analysis to men who were lean. We have previously published in NHANES III
and NHANES 1999 to 2004 on factors associated with estradiol levels, including adiposity
[27, 28]. Thus, to capture estradiol levels in men, we restricted the analysis to men who were
the most likely to be lean, based on having both a normal BMI and a normal WC. We also
restricted the analysis to men who were more likely to be healthy, specifically those without
diagnoses of cardiovascular disease, diabetes, and cancer. Finally, we restricted the analysis
to men who did not currently smoke, given that male smokers tend to have higher total and
free estradiol, including men in NHANES III [17].
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Estrogen levels, especially free estradiol, generally decrease with age in men. We pre-
viously reported decreases cross-sectionally across age in NHANES III [29] and in NHANES
1999 to 2004 [11]. Age-dependent decreases in estradiol may be partially due to age-related
decreases in testosterone and increases in SHBG [30–32]. However, these estrogen-reducing
events may be countered by the increasing prevalence of proestrogenic states with age,
especially age-dependent increases in body fat and in the prevalence of common chronic
diseases such as cardiovascular disease and cancer. Up to 80% of estrogen is produced outside
the testes through the aromatization of testosterone in adipose cells; thus, the production of
estradiol depends on the amount of body fat in men [33].
In the United States, the prevalence of conditions that decrease testosterone levels [27, 34]
continues to rise, and thus the target group of men for testosterone supplementation is
expanding. For example, according to the National Center for Health Statistics, the prev-
alence of diabetes (diagnosed and undiagnosed) in adult men increased from 8.6% in 1988 to
1994 to 13.2% in 2011 to 2014, and the prevalence of obesity in men ages$20 years increased
from 19.5% in 1988 to 1994 to 34.5% in 2013 to 2014 [35]. Therefore, as chronic diseases that
influence the likelihood of testosterone insufficiency become more prevalent in adult men, it
may be important to consider the possible implications of any increase in the prescription of
testosterone supplementation on the resultant increases in estradiol in older men.
Given the age-estrogen decline, an open question is whether older adult men should have
the same estradiol levels as younger men for optimal overall and metabolic health, which
tends to deteriorate with age. A priori, we decided to present total and free estradiol con-
centrations stratified by age irrespective of whether the optimal target turns out to be levels
in younger men (higher concentration) or older men (lower concentration).
This study reports on typical estrogen levels in men without common proestrogenic,
proandrogenic, or antiandrogenic states in a nationally representative sample of men overall
and by race and ethnicity. Other studies have reported estrogen levels by age but not
specifically in healthy men. The most extensive of these reports is a cohort of.10,000 men of
predominantly European ancestry ages 35 to 100 years old, pooled from three population-
based studies of community-dwelling men in three Australian cities [36]. In that study,
median total estradiol concentrations of men aged ,65, 65 to,75, 75 to,85, and$85 years
old were 88 pmol/L (24 pg/mL), 77 pmol/L (21 pg/mL), 81 pmol/L (22 pg/mL), and 85 pmol/L
(23 pg/mL), respectively. In a study of 572 German men who were blood donors and older
sports club members with BMI ,30 kg/m2 and without chronic illness, mean total estradiol
levels (mean6 SD) varied by age decade (20 to 29, 30 to 39, 40 to 49, 50 to 59, 60 to 69, and 70
to 80 years), and were 102.9 6 23.43 (28.03 6 6.38 pg/mL), 94.17 6 18.01 (25.65 6 4.91 pg/
mL), 90.76 6 18.33 (24.72 6 4.99 pg/mL), 81.02 6 15.33 (22.07 6 4.12 pg/mL), 78.82 6 16.33
(21.47 6 4.45 pg/mL), and 80.37 6 17.14 (21.89 6 4.67 pg/mL) pmol/L, respectively [37]. The
medians andmeans in all men and in nonsmoking leanmen in NHANES III and in NHANES
1999 to 2004, which measured estradiol by electrochemiluminescence immunoassays, were
notably higher than the medians in the Australian study, which measured estradiol by using
liquid chromatography–mass spectrometry [36], and the means in the German study, which
measured estradiol via radioimmunoassay [37].
The major strength of our study is the use of NHANES data. Both NHANES III and
NHANES 1999 to 2004 used stringent sampling designs, and we applied sampling weights so
that the findings can be generalized to the US population. Because of the wealth of in-
formation available in NHANES and because factors influencing estradiol had been pre-
viously studied in NHANES, to generate typical medians and distributions for healthy men,
we were able to make exclusions based on factors observed to influence estradiol. Never-
theless, our study has several aspects that warrant discussion. Although we used data on
serum estradiol measured in the same laboratory with the same assay method, mass
spectrometry is the current standard method for research. Nevertheless, the laboratory
method in the current study is commonly used clinically, and the kits that were used are
approved by the US Food and Drug Administration for clinical use. Measurement of serum
total estradiol tends to be less precise than that of other hormones because of its low
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concentration inmen. Althoughwe estimated free estradiol, the estimationmethod used each
man’s measured concentration of SHBG and albumin. Because we used existing data, sample
sizes were fixed, which led to small counts for some analyses when stratified by race and
ethnicity. We were limited to the most prevalent racial and ethnic groups in the NHANES
surveys of 1998 to 1991 and 1999 to 2004; thus, we were not able to provide information
relevant to Asian men or American Indian/Alaska Native men.
In conclusion, we assessed the age-specific distributions of total and free estradiol in
NHANES III and 1999 to 2004. Our goal was to report typical estradiol levels in a nationally
representative population of healthy men to support the implementation of clinical
guidelines for serum estradiol concentrations for men with symptomatic testosterone de-
ficiency who are candidates for testosterone supplementation, and formen in general for good
health. With respect to the former use, we envision that consensus guideline developers
might need this information. With respect to the latter use, clinical consensus would be
needed to define the array of estrogen-associated health states that should be considered and
how their relative harms and benefits should be included when optimizing target serum
estradiol levels for good health in general based on never-smoking, lean men without
comorbidities. Given the recognized racial and ethnic variability in circulating estradiol
levels, more work is needed, including by future measurement of estradiol concentrations in
existing samples from more recent NHANES surveys, to report with precision population-
specific estradiol levels.
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